Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Claims Progress, Asks Investors For Patience

Executive Summary

The Canadian specialty pharma has exceeded its near-term debt-reduction goals, but are its plans for a return to growth grounded in reality? Market analysts recommend caution, but see some reason for optimism.
Advertisement

Related Content

Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
Finance Watch: Despite Bad News, IPOs And Public Offerings Keep Flowing
Stock Scan February 2018: Wet But Above Water
Valeant Sees Sunshine On Cloudy Day, But Dermatology Recovery Just Starting
Deal Watch: Valeant Continues Divestment Spree By Selling Obagi At A Loss
Valeant On Track With Debt-Reduction Goals, But Will It Be Enough?
Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market
Siliq Probably Isn't The Light At The End Of Valeant's Tunnel

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel